DBV Technologies develops the VIASKIN® patch, an epicutaneous immunotherapy (EPIT) platform that delivers tiny amounts of allergen to the skin to re‑educate the immune system. The patch is being tested in clinical trials for peanut and milk allergies, aiming to provide a safer, long‑term treatment option for patients with food allergies.
Funding
$532.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Food allergies such as peanut and cow’s milk protein allergy affect a significant portion of the population, especially children, and current management relies on strict avoidance and emergency medication, offering no durable tolerance. Existing oral immunotherapy requires daily dosing and carries risk of adverse reactions, limiting its practicality and acceptance.
Solution
DBV Technologies has created VIASKIN®, an epicutaneous immunotherapy (EPIT) platform that delivers ultra‑low doses of allergen directly onto the skin via a patch. By presenting the antigen to immune cells in the epidermis, the patch aims to re‑educate the immune system and induce long‑lasting desensitisation without the need for oral ingestion. The approach is being evaluated in a Phase 3 trial for peanut allergy (DBV712) and completed Phase 1/2 and Phase 2a studies for a milk allergy patch (DBV135). VIASKIN® is designed for use in pediatric and adolescent patients, offering a non‑invasive, clinic‑administered or home‑use option that could reduce the burden of daily dosing and improve safety compared with oral therapies.
Target Audience
Primary customers are allergists, pediatricians, and clinical centers treating patients with peanut or cow’s milk protein allergy, as well as pharmaceutical partners interested in licensing the EPIT platform for other allergens.
Features
- EPIT technology that applies minute, controlled amounts of allergen to the skin, targeting Langerhans cells for immune modulation
- Stand‑alone adhesive patch format suitable for self‑application or administration by healthcare providers
- Clinical-grade formulation validated in multiple age cohorts, including infants as young as 1 year for peanut allergy
- Designed for a short daily wear period (typically 24 hours) with minimal systemic exposure, reducing adverse reaction risk
- Scalable platform that can be adapted to additional food allergens and potentially other immune‑mediated conditions